Kirby McInerney LLP is investigating potential claims against NPS Pharmaceuticals, Inc. (“NPS” or the “Company”) NPSP concerning the proposed acquisition of the Company by Shire plc (“Shire”) (LSE: SHP) SHPG. Under the terms of the merger agreement, NPS stockholders will receive $46.00 in cash for each share of NPS common stock they own, valuing the transaction at approximately $5.2 billion.
The investigation concerns whether the NPS Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company's common stock.
If you are a NPS stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at mfortunato@kmllp.com, or telephone at (212) 699-1141, or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
Kirby McInerney LLP
J. Brandon Walker, Esq., 212-699-1145
bwalker@kmllp.com
or
Melissa
Fortunato, Esq., 212-699-1141
toll free: 888-529-4787
mfortunato@kmllp.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.